Key result
Type 2 diabetes in peritoneal dialysis patients is linked to ~100% higher metabolic syndrome prevalence.
Why the study?
The prevalence of metabolic syndrome and its association with cardiovascular morbidity in patients undergoing continuous ambulatory peritoneal dialysis was not well established.
Population
37 patients on peritoneal dialysis for > 3 months (25 type 2 diabetic, 12 non-diabetic)
Comparison
Type 2 diabetic patients vs non-diabetic patients with metabolic syndrome
Design
Cohort study
Authors
Loading...
Metabolic syndrome prevalence in peritoneal dialysis patients was associated with LVH in type 2 diabetes; hypothesis-generating, requiring prospective validation before clinical adoption.
Cohort (n=37)
Absolute Event Rate: 100% vs 50%
p-value: p=0.0005
Metabolic syndrome is highly prevalent in peritoneal dialysis patients, particularly those with type 2 diabetes, and is associated with increased rates of left ventricular hypertrophy.
Rašić et al. (2010) conducted a cohort in Peritoneal dialysis (n=37). Type 2 diabetes vs. Non-diabetic patients was evaluated on Development of metabolic syndrome at the end of follow-up (p=0.0005). Type 2 diabetes in peritoneal dialysis patients was associated with a significantly higher prevalence of metabolic syndrome at follow-up compared to non-diabetic patients (100% vs 50%, p=0.0005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: